You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Baxter
AstraZeneca
Moodys
Express Scripts

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

HYDROCHLOROTHIAZIDE; VALSARTAN - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for hydrochlorothiazide; valsartan and what is the scope of freedom to operate?

Hydrochlorothiazide; valsartan is the generic ingredient in two branded drugs marketed by Novartis, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Prinston Inc, Watson Labs Teva, and Zydus Pharms, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for hydrochlorothiazide; valsartan. Sixteen suppliers are listed for this compound. There is one tentative approval for this compound.

Recent Clinical Trials for HYDROCHLOROTHIAZIDE; VALSARTAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Farma de Colombia SAPhase 3
Damanhour UniversityN/A
Tehran University of Medical SciencesPhase 3

See all HYDROCHLOROTHIAZIDE; VALSARTAN clinical trials

Generic filers with tentative approvals for HYDROCHLOROTHIAZIDE; VALSARTAN
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial25MG;320MGTABLET;ORAL
  Start Trial  Start Trial12.5MG;320MGTABLET;ORAL
  Start Trial  Start Trial25MG;160MGTABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for HYDROCHLOROTHIAZIDE; VALSARTAN
Paragraph IV (Patent) Challenges for HYDROCHLOROTHIAZIDE; VALSARTAN
Tradename Dosage Ingredient NDA Submissiondate
DIOVAN HCT TABLET;ORAL hydrochlorothiazide; valsartan 020818 2007-02-07
DIOVAN HCT TABLET;ORAL hydrochlorothiazide; valsartan 020818 2005-12-02

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE; VALSARTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc VALSARTAN AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; valsartan TABLET;ORAL 203026-003 Mar 21, 2013 DISCN No No   Start Trial   Start Trial   Start Trial
Alembic Pharms Ltd VALSARTAN AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; valsartan TABLET;ORAL 201662-004 Mar 21, 2013 AB RX No No   Start Trial   Start Trial   Start Trial
Macleods Pharms Ltd VALSARTAN AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; valsartan TABLET;ORAL 203145-004 Apr 19, 2013 AB RX No No   Start Trial   Start Trial   Start Trial
Prinston Inc VALSARTAN AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; valsartan TABLET;ORAL 206083-004 Feb 8, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs Teva VALSARTAN AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; valsartan TABLET;ORAL 091519-001 Mar 21, 2013 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for HYDROCHLOROTHIAZIDE; VALSARTAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis DIOVAN HCT hydrochlorothiazide; valsartan TABLET;ORAL 020818-004 Apr 28, 2006   Start Trial   Start Trial
Novartis DIOVAN HCT hydrochlorothiazide; valsartan TABLET;ORAL 020818-001 Mar 6, 1998   Start Trial   Start Trial
Novartis DIOVAN HCT hydrochlorothiazide; valsartan TABLET;ORAL 020818-003 Jan 17, 2002   Start Trial   Start Trial
Novartis DIOVAN HCT hydrochlorothiazide; valsartan TABLET;ORAL 020818-002 Mar 6, 1998   Start Trial   Start Trial
Novartis DIOVAN HCT hydrochlorothiazide; valsartan TABLET;ORAL 020818-005 Apr 28, 2006   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Colorcon
Baxter
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.